AFP and hepatocellular carcinoma: The present study aimed to evaluate the ability of a previously proposed TM score involving AFP, AFP-L3, and DCP as TMs [14,15] in predicting the prognosis and therapeutic efficacy in HCC patients administered Atez/Bev as first-line treatment.